Maxime Dely: What If Whole Blood Became the Standard Again in Massive Transfusion?
Maxime Dely, Therapeutic Solutions Sales Consultant at Terumo Blood and Cell Technologies, shared a post on LinkedIn:
“What if whole blood became the standard again in massive transfusion?
In the management of massive hemorrhage, current protocols are well established: alternating red blood cell concentrates, plasma, and platelets – a structured sequence designed to approximate whole blood.
But an important question is increasingly being raised:
Why not use leukoreduced whole blood directly?
The advantages are clear:
- A product that is inherently complete and balanced
- Simplified logistics (single storage condition and unified shelf-life considerations)
- More efficient inventory management
From a scientific standpoint, several recent studies indicate that whole blood offers efficacy comparable to component therapy, particularly regarding early survival and correction of coagulopathy.
Beyond clinical outcomes, this also prompts broader reflection on our organizational models.
And you – have your institutions already begun exploring this shift?”
Find more posts featuring Maxime Dely on Hemostasis Today.
-
Sep 25, 2026, 09:49Haley Coleman: Volunteering to Support Hemophilia Awareness
-
Sep 25, 2026, 08:55Hitarth Mehta: BHMS Students Gain Practical Exposure to Haemophilia Diagnosis
-
Sep 25, 2026, 07:25Varun Capoor: How Therapeutic Apheresis and Transfusion Medicine Can Complement Clinical Management in SCD
-
Sep 25, 2026, 07:14Manshi Kesharwani: SAK-GQDs Modulate Thrombus Burden and Endothelial Function in Deep Vein Thrombosis
-
Sep 25, 2026, 06:20Farjah Hassan Algahtani: How Can We Better Identify Patients at Risk of Blood Clots after Metabolic and Bariatric Surgery?
-
Sep 25, 2026, 05:59Carla Lewis: Kids Conquering Sickle Disease Joins Nemours Children’s Hospital for 2nd Annual Awareness Event
-
Sep 25, 2026, 05:47Omid Seidizadeh: Evolutionary Constraint and Population Variation Across Coagulation Genes
-
Sep 25, 2026, 05:40Gerald Bertrand: Presenting UMi-NGS Non-Invasive Foetal HPA Genotyping at DGTI 2026
-
Sep 25, 2026, 05:33Urge Congress to support the Sickle Cell Disease Comprehensive Care Act – ASH